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Objectives: This study was undertaken to assess accelerated multimodality therapy
in patients with IIIA and IIIB non–small cell lung cancer in terms of toxicity,
feasibility, response, survival, and recurrence (value) and to identify predictors of
pathologic response and improved survival.
Methods: Between October 1994 and September 2000, a total of 105 patients with
stage pIIIA (n  78) or pIIIB (n  27) non–small cell lung cancer were enrolled in
a study of accelerated multimodality therapy, consisting of hyperfractionated radio-
therapy with concurrent chemotherapy (paclitaxel and cisplatin) followed by resec-
tion and postoperative chemoradiation. Multivariable correlates of pathologic
response and survival were assessed.
Results: Toxic effects related to induction therapy necessitated hospitalization in
40% of patients (n  42); treatment-related mortality was 9% (n  9). With respect
to feasibility, 100% of patients completed induction therapy, 93% (n  98) of
cancers were operable, 79% (n  83) of cancers were curatively resectable, and
77% (n  81) of patients completed all therapy. Sterilization of mediastinal nodes
was similar (P  .6) for pN2 (35%) and pN3 (30%) disease. Median, 2-year, and
5-year survivals were 27 months, 53%, and 32%, respectively. Locoregional recur-
rence, distant recurrence, and both were seen in 6% (n  6), 45% (n  47), and 3%
(n  3) of patients, respectively. Pathologic response was not predictable. Nodal
status predicted incrementally decreasing survival for patients with cancers down-
staged to ypN0 or ypN1 (n  35) versus ypN2 (n  44) versus ypN3 (n  20; P 
.001). In addition, advancing age, squamous histologic type, and higher pT pre-
dicted poorer survival.
Conclusions: Accelerated multimodality therapy is equally valuable in IIIA and IIIB
non–small cell lung cancers. Despite unpredictable response to induction therapy,
younger patients and those with nonsquamous histologic type, sterilization of
mediastinal lymph nodes, and lower pT benefit most. A ypN2 stage reduces but does
not preclude long-term survival.
For the past decade, the approach to therapy for both stage IIIA andstage IIIB non–small cell lung cancer (NSCLC) at The ClevelandClinic Foundation has differed from that of previous clinical trials.1-3An accelerated multimodality protocol was implemented4,5 with theaims of improving feasibility, pathologic response, and survival andof reducing tumor recurrence with acceptable toxicity (value). Accel-
erated multimodality therapy consists of induction chemotherapy and concurrent
hyperfractionated radiotherapy,6,7 resection with unilateral lymphadenectomy, and
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accelerated adjuvant chemotherapy with concurrent hyper-
fractionated radiotherapy. Objectives of this study were to
assess accelerated multimodality therapy in patients with
stage IIIA and IIIB NSCLC in terms of toxicity, feasibility,
tumor response, survival, and tumor recurrence (value) and
to identify predictors of pathologic response and improved
survival within this group.
Patients And Methods
Patients
Between October 1994 and September 2000, a total of 105
patients (58% male, mean age 57  10 years) with IIIA
(n 78) or IIIB (n 27) NSCLC were enrolled in the study
of accelerated multimodality therapy (Table 1). Only 7 (7%)
had cT4 disease (involvement of superior vena cava [n 2]
and mediastinum [n 5]; surgical staging for these patients
indicated pN0 disease in 3 cases, pN2 in 3, and N3 in 1. Of
the 105 patients, 102 (97%) had stage III disease because of
mediastinal nodal involvement.
Eligibility and Staging
All patients had histologic or cytologic diagnosis of NSCLC
and were evaluated by a thoracic surgeon, medical oncolo-
gist, and radiation oncologist. Radiographic evaluation in-
cluded chest radiographs; head, chest, and abdominal com-
puted tomography; and radionuclide bone scanning.
Beginning in 1999, whole-body positron-emission tomo-
graphic scanning with fluorodeoxyglucose tagged with flu-
orine 18 was used. Surgical staging was performed in all
cases. Pretreatment stage was assigned according to Amer-
ican Joint Committee on Cancer lung cancer guidelines.8
Patients with stage III (pN2 or pN3) disease, as well as those
with cT4 tumors, exclusive of malignant pleural effusions
and separate tumor nodules in the same lobe, were included.
The study was approved by The Cleveland Clinic Foun-
dation’s Institutional Review Board and was reviewed an-
nually. Written informed consent was obtained from each
patient before therapy began.
Treatment
Accelerated induction therapy. Induction therapy con-
sisted of a 12-day course of concurrent chemoradiotherapy,
as previously reported elsewhere (Figure 1).5 A 4-day con-
tinuous infusion of cisplatin (20 mg · m2 · d1) and a
24-hour infusion of paclitaxel (175 mg · m2) given on day
1 were administered to inpatients. Concurrent accelerated
fractionation radiation therapy consisting of twice daily
1.5-Gy fractions given at least 6 hours apart were adminis-
tered Monday through Friday during the first 2 weeks of
treatment.
Four weeks after commencement of induction therapy,
clinical reassessment included repeat chest computed tomo-
graphic scan and pulmonary function testing. Evidence of
locoregional progression was defined as an increase greater
than 25% in the sum of the crossed diameters of measurable
tumor. Such progression or development of new distant
metastatic disease excluded resection.
Resection. Resection consisted of lobectomy, bilobec-
tomy, or pneumonectomy with complete unilateral media-
stinal lymphadenectomy.
Accelerated adjuvant therapy. Within 6 to 8 weeks of
resection, patients underwent a 2-week course of acceler-
ated concurrent chemoradiotherapy similar to induction
therapy (Figure 1). There were no chemotherapy dose re-
ductions. Total adjuvant radiotherapy dose was between 30
and 33 Gy. Total spinal cord dose was 45 Gy with lateral
and oblique fields; posterior spinal cord blocks were not
used.
Assessment
Value of accelerated multimodality therapy was assessed in
relation to its risks and benefits.
TABLE 1. Patient and tumor characteristics (n  105)
Variable No. %
Age (y)
Mean  SD 57 10
Median and range 59 (31-75)
Male (No.) 61 58
Histologic type (No.)
Adenocarcinoma 40 38












Figure 1. Treatment schema for accelerated hyperfractionated
chemoradiotherapy followed by resection and adjuvant, consoli-
dative chemoradiation for patients with stage IIIA and stage IIIB
NSCLC. Cisplatin dose was 20 mg · m2 · d1 for 4 days and
paclitaxel dose was 175 mg · m2 as 24-hour infusion. CDDP,
Cisplatin; BID RT, twice-daily radiotherapy at 1.5 Gy per fraction.
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Toxicity. Toxicity of induction and toxicity of adjuvant
therapy were assessed by symptoms, signs, hospitalization,
and related mortality. Surgical morbidity and mortality were
included as components of toxicity.
Feasibility. Feasibility was assessed by ability of pa-
tients to complete induction therapy, operability, curative
resectability, and ability to complete adjuvant therapy.
Tumor response. Tumor response was defined as
downstaging of cT or pN. Complete response was defined as
ypT0N0.8 Partial response was defined as reduction in cT or
pN without a reciprocal increase in the other (progressive
disease). For patients with pN3 disease, nonresponse was
defined as ypN2.
Survival and tumor recurrence. Survival and tumor
recurrence were assessed by patient follow-up. Patients
were followed up every 3 months with clinical examination
and chest radiographs. Additional testing was directed by
clinical findings. Survivals from the time of commencement
of induction therapy and after surgery were assessed by both
the Kaplan-Meier method and a parametric method that
resolves the number phases of instantaneous risk of death
(hazard function).9 Recurrence was classified as locore-
gional (tumor within the ipsilateral thorax), distant (tumor
outside the ipsilateral thorax), or both. The common closing
date was October 17, 2001. Median follow-up was 18
months (range 2-79 months).
Data Analysis
Descriptive statistics included mean  SD and median and
quartiles for continuous variables, with frequencies and
percentages for categorical variables.
Predictors of pathologic response. Factors predictive
of pathologic response were sought by multivariable logistic
regression analysis with a stepwise selection procedure for
which retention in the final model required P  .05. Factors
considered potential predictors of pathologic response were
age, gender, race, pretreatment T, pretreatment N, pretreat-
ment stage, cell type, and clinical response.
Predictors of survival. The strategy to identify predic-
tors of survival proceeded in two steps with multiphase
hazard function methodology.9 At both steps we incorpo-
rated demographic characteristics, tumor histologic type,
operative resection (pneumonectomy vs lobectomy), and
date of therapy. Details are given in Appendix 1.
First, we focused on individual components of final
pathologic TNM classification (ypTNM) and on the differ-
ences between pretreatment cT, pN, and ypTNM. We then
added the variable pretreatment stage IIIB to test whether
initial stage influenced survival beyond TNM classification.
Second, we added to the previous the postresection stage
grouping and pathologic response to treatment (complete,
partial, none, or progressive disease). Then we again added
the variable for pretreatment stage IIIB. The equation from
this second multivariable analysis was solved for various
combinations of risk factor values that illustrate the constel-
lation of characteristics leading to good and to poor sur-
vival, as described by Kirklin and Barratt-Boyes.10
Results
Value of Therapy
Toxicity. During induction therapy, most patients expe-
rienced nausea, vomiting, mucositis or dysphagia, and neu-
tropenia (Table 2), although grade III or IV symptoms were
infrequent. Forty-two patients (40%) required hospitaliza-
tion for febrile neutropenia. There were no toxicity-related
deaths from induction therapy. Although toxicity was com-
mon, it was manageable.
Surgical mortality was 7%. Four patients died of pneu-
monia or adult respiratory distress syndrome, 1 died of
postpneumonectomy bronchopleural fistula, 1 died of mul-
tisystem organ failure after perforation of a duodenal ulcer,
and there was 1 sudden death at home within 30 days of
surgery. Thirty patients (31%) had postoperative complica-
tions (Table 2).
There were 2 toxicity-related deaths during adjuvant
therapy, 1 from necrotizing pneumonia with subsequent
TABLE 2. Treatment-related toxicity
Phase and type No. %
Induction therapy (n  105)
Nausea and vomiting 92 88
Grade III/IV 4 4
Mucositis or dysphagia 88 84
Grade III/IV 11 10
Neutropenia (1000 cells  mm3) 95 90
Hospitalized 42 40
Renal 5 5
Toxicity-related death 0 0
Surgery (n  98)
Mortality 7 7
Morbidity* 30 31
Supraventricular arrhythmia 18 18
Recurrent laryngeal nerve palsy 6 6
Pneumonia or adult respiratory distress syndrome 3 3
Bronchopleural fistula or prolonged air leak 3 3
Deep wound infection 2 2
Reoperation for bleeding 1 1
Adjuvant therapy (n  84)†
Nausea and vomiting 75 89
Grade III/IV 10 12
Mucositis or dysphagia 51 61
Grade III/IV 7 8
Neutropenia (1000 cells  mm3) 80 95
Hospitalized 30 36
Myocardial infarction 1 1
Toxicity-related death 2 2
*Patients could have more than 1 complication.
†Of 98 patients undergoing resection, 84 received adjuvant therapy. An
additional 4 patients with inoperable disease received adjuvant therapy.
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bronchopleural fistula and 1 from postemetic esophageal
perforation. One patient had a nonfatal myocardial infarc-
tion related to occult coronary artery disease. Other toxic
effects were similar to those of induction therapy (Table 2).
Feasibility. All patients completed induction therapy in
12 days (100%). Ninety-eight patients (93%) were operative
candidates. Among the 7 inoperable cases, 4 patients had
locoregional progression, 2 had new distant metastatic dis-
ease, and 1 was considered medically unfit for surgery.
Eighty-three patients (79%) underwent curative resec-
tion. Of 15 patients who did not undergo curative resection,
6 had incomplete resection, 2 had residual N3 disease, 2 had
intrapulmonary metastatic disease, and 5 had extensive in-
volvement of the superior vena cava (n  3), descending
aorta (n  1), or muscular chest wall (n  1). Curative
resections included pneumonectomy (n  36), bilobectomy
(n  5), and lobectomy (n  42).
Of the 91 operative survivors, 84 (92%) commenced
adjuvant therapy. Among the 7 who did not receive adjuvant
therapy, 2 had protracted postoperative courses and 5 had
disease progression. Among the 84 patients who began
adjuvant therapy, 2 did not complete therapy because of
toxicity, 1 died, and 1 had disease progression. One addi-
tional toxicity-related death occurred soon after adjuvant
therapy was completed. Thus 81 of the 105 enrolled patients
(77%) completed and survived accelerated multimodality
therapy.
Tumor response. There were no clinically determined
complete responses, probably because of the brief interval
between induction therapy and reassessment. Sixty-two per-
cent of patients had a measurable partial response, defined
as a more than 50% reduction in the sum of the crossed
diameters of measurable tumor. Thirty-one percent had sta-
ble disease, and 6% had progression. Pathologic examina-
tion of the resected tissue demonstrated a complete response
in 12 patients (11%), a partial response in 43 (41%), stable
disease in 33 (31%), and progressive disease in 17 (16%).
Overall, 35 patients had sterilization of mediastinal
lymph nodes (downstaged; Table 3). This response occurred
in similar proportions of patients with IIIA (n  27/78,
35%) and IIIB (n  8/27, 30%) disease (P  .6). Postresec-
tion tumor classifications are listed in Appendix Table 1.
Survival. Median, 1-, 3-, and 5-year survivals for all
patients from commencement of therapy were 27 months,
67%, 39%, and 30%. Survivals of the 98 patients undergo-
ing operation were 70%, 42%, and 26% at 1, 3, and 5 years
(Figure 2, A). The instantaneous risk of death (hazard func-
tion) is depicted in Figure 2, B. It consisted of an initial
period of high risk lasting approximately 6 months and a
constant hazard of 25% per year thereafter. Median survival
among the 15 patients who did not undergo curative resec-
tion was 18 months. Survivals of the 81 patients who
completed multimodality therapy were 77%, 42%, and 39%
at 1, 3, and 5 years.
Tumor recurrence. Fifty-six patients had recurrent
NSCLC, and 47 of them had died as of close of follow-up.
Six recurrences (6%) were locoregional, 47 (45%) were
distant metastatic, and 3 (3%) were both.
Predictors of Pathologic Response
No pretherapy patient, staging, or tumor factor was predic-
tive of pathologic response.
Predictors of Survival
The most important predictor of survival was pathologic
stage (P  .001; Figure 3). Patients with disease down-
staged to ypN0 (pathologic stages 0, I) or ypN1 (pathologic
stage II) had 55%  10% 5-year survival, whereas patients
with persistent stage IIIB disease were unlikely to survive 2
years (18%  9%). A statistically distinctive and novel
intermediate cohort in this study was the group with residual
stage IIIA, ypN2 disease. These patients had a median
survival of 27 months, with 31%  9% 5-year survival.
In the first analysis of ypTNM, incremental risk factors
for death included older age, larger tumor after induction
therapy (higher ypT), more extensive regional lymph node
metastases (higher ypN), and squamous cell carcinoma
(Table 4). After accounting for these factors, survival was
unaffected by whether the disease had been stage IIIA or
IIIB before treatment (P  .8) or by the magnitude of
reduction of T or N with induction therapy (P  .15 and
P  .8, respectively).
The second analysis, including postresection stage
grouping, added to the previously mentioned risk factors’
lack of pathologic response to induction therapy and post-
resection stage IIIB and IV (ypIIIB/IV; Table 4). Survival
benefit was equivalent for patients with partial and complete
response. Pretreatment stage IIIA versus IIIB was not a
predictor of survival (P  .6).
A young patient with either large cell cancer or adeno-
carcinoma whose tumor was sterilized (downstaged) with
induction therapy had excellent survival (Figure 4), regard-
less of whether the clinical stage was IIIA or IIIB before







No. % No. %
0 10 13 2 7
I 13 17 5 19
II 4 5 1 4
IIIA 41 53 3 11
IIIB 5 6 15 56
IV 5 6 1 4
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treatment. However, an older patient with squamous carci-
noma that did not respond to treatment and continued in
pathologic stage IIIB had limited survival (Figure 4).
Discussion
Value of Therapy
Value of therapy is an important but abstract concept that is
difficult either to rigorously define or to quantify. However,
it focuses attention on risks and benefits of therapy. Al-
though a rigorous mathematical description and evaluation
of value cannot be formulated, many of the medical com-
ponents of value can be measured, even if not weighted, and
predictors of value, such as favorable response, can be
sought.
Toxicity (risk). Induction therapy followed by surgery
was toxic, but toxicity was manageable and not fatal. De-
spite toxicity, surgery was not delayed, and surgical mor-
tality was comparable to that with other protocols. Morbid-
ity occurred in nearly every third patient, but more than half
were atrial arrhythmias. Thus although morbidities were
Figure 2. Postoperative survival after accelerated chemoradiotherapy. A, Survival. Each circle represents death
positioned on vertical axis according to Kaplan-Meier estimator. These are accompanied by vertical bars representing
asymmetric 68% confidence limits (equivalent to 1 SE). Numbers in parentheses represent survivors at that interval.
Smooth curve is parametric estimate of survival enclosed within dashed asymmetric 68% confidence bands. B, Hazard.
Instantaneous risk of death (hazard function) is represented by solid curve enclosed within dashed 68% confidence
limits. Although early risk is high, this hazard is of short duration, resulting in few early deaths.
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multiple, they seemed not to be excessive. Toxicity of
adjuvant therapy was similar to that of induction therapy,
but in this final phase of therapy, toxicity-related deaths did
occur. The overall observed treatment-related mortality of
9% compares favorably with the 10% reported by the mul-
ticenter Southwest Oncology Group (SWOG), which fol-
lowed a more standard protocol of induction chemoradia-
tion and resection.1
Feasibility. Induction therapy followed by resection
was feasible. Resectability in 79% of cases is superior to
rates reported after induction chemotherapy alone in stage
IIIA N2 NSCLC11-13 and similar to the rate reported by
SWOG after neoadjuvant chemoradiotherapy for both stage
IIIA and stage IIIB disease.1 This accelerated strategy was
feasible even though most cases of IIIB disease were pN3,
unlike with SWOG 8805.
An advantage of accelerated multimodality therapy is
superior patient compliance and less attrition as a result of
accumulated toxic effects, increasing feasibility. Seventy-
seven percent of patients completed all prescribed treat-
Figure 3. Survival by pathologic stage. Both Kaplan-Meier (symbols) and parametric (curves) survival estimates
are depicted as in Figure 2, A. Parametric estimates are truncated when remaining survivors are few. Patients with
pathologic stage 0 to II had survival superior to those with residual N2 disease (stage IIIA), who in turn had longer
survival than did nonresponders (stage IIIB, P < .001).
TABLE 4. Incremental risk factors for death after resection
Risk factor Coefficient  SD P Reliability (%)
Analysis 1
Older age* 3.8 1.06 .0004 75
Larger tumor (ypT) 0.76 0.146 .0001 70
More extensive regional lymph node metastasis (ypN)† 0.022 0.0086 .01 68
Squamous cell carcinoma 0.69 0.32 .03 53
Analysis 2
Older age* 3.4 1.09 .002 72
Larger tumor (ypT) 0.33 0.195 .09 55
ypIIIB/IV‡ 0.82 0.38 .03 62
Squamous cell carcinoma 0.81 0.32 .01 78
No pathologic response to induction chemoradiotherapy§ 0.99 0.34 .003 56
*Inverse transformation (50/age).
†Natural exponential transformation exp (ypN).
‡Postresection stage after induction therapy.
§Survival benefit.
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ment, whereas only 45% of patients enrolled in Cancer and
Leukemia Group B 8935 completed the prescribed thera-
py.11 Although a similar proportion of patients in SWOG
8805 (78%) completed induction therapy, adjuvant therapy
was prescribed and given to only 37 (29%) of 126 trial
participants.1
Response. Clinical response to accelerated induction
therapy was similar to the response to three cycles of
induction chemotherapy alone14 or to two cycles of concur-
rent chemoradiotherapy.1,15 The 12-day induction protocol
had pathologic response (complete and partial) and nodal
downstaging similar to those of other concurrent regimens
lasting 33 days15 and 36 days.1
Survival. Accelerated multimodality therapy produced
a median survival 1 year longer than that seen in SWOG
8805, a phase II trial that also enrolled patients with both
stage IIIA and IIIB disease.1 Long-term survival (5 years)
was seen in 30% of patients, whereas it was 26% at 3 years
in SWOG 8805.1
Recurrence. Local control was excellent, with only 9%
of patients having cancer recurrence in the ipsilateral thorax,
compared with a 30% local recurrence rate reported by
Grunenwald and colleagues15 in patients with IIIB disease
and a 20% rate in SWOG 8805.1Distant metastases remain
the most common and discouraging problem. Nearly half of
the patients had systemic recurrence, usually in the brain, a
common finding with multimodality treatment of stage IIIA
and IIIB disease.1,2,11-15
Predictors. Pathologic downstaging was the most im-
portant predictor of improved survival. Approximately a
third of patients had their disease downstaged to N0 or N1,
with a 5-year survival of almost 55%. This is similar to
survival among patients with newly diagnosed stage IB or
stage IIA NSCLC.16 Mediastinal nodal sterilization pro-
vided equivalent survival regardless of whether the disease
was initially N2 or N3.
Persistent mediastinal nodal metastasis has been reported
as a reliable predictor of death,1,2,15 with 18% 3-year sur-
vival. These results question the benefit of resection in the
absence of nodal downstaging.
In contrast, this report establishes an important middle
ground. Patients with residual N2 disease (ypN2 status)
after accelerated induction therapy had a median survival of
27 months, with 31% 5-year survival. One possible expla-
nation for this near doubling of survival despite persistent
N2 disease is the accelerated time frame. Indeed, some
patients with microscopic residual nodal disease at the time
of resection might in fact have had sterilization if several
more weeks had elapsed before removal. This is reflected in
a lower percentage of apparent pathologic downstaging in
our study (33%) than the 67% and 53% rates reported after
standard induction therapy for N2 disease.1,2 However, the
Figure 4. Good risk and poor risk patients. Shown at upper portion of graph is 45-year-old patient whose
adenocarcinoma was sterilized by accelerated chemoradiotherapy. For comparison, we present same patient
profile except with squamous cell carcinoma. Survival at bottom of graph is for 65-year-old patient who did not
respond to therapy and was found to have T4 tumor at surgery. Two curves represent squamous and nonsquamous
tumor histologic types.
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rate is similar to that observed after induction therapy for
stage IIIB cancers.14,15
Strengths and Limitations
In this analysis we have highlighted the value of accelerated
multimodality therapy for stage III NSCLC. It is difficult to
know whether the enhanced overall survival is related to
limited toxicity, increased feasibility, or better pathologic
response. Hazard function analysis allowed treatment-
related death to be distinguished from cancer-related death.9
In Figure 2, B, the area under the early, steep portion of the
curve is the risk of toxicity-related death. Its height is
governed by the toxicity of treatment (concurrent chemora-
diation and surgery), and its width reflects duration of
therapy. Accelerated therapy results in a brief period of
treatment-related death risk. After completion of treatment,
a steady-state risk of death reflects the ongoing and unre-
mitting effects of residual or recurrent cancer.
Enhanced feasibility and response with manageable tox-
icity and prolonged survival are arguably the central
strengths of accelerated multimodality therapy for both
stage IIIA and stage IIIB NSCLC. These depend on dedi-
cated multidisciplinary care and come with some unex-
pected costs, especially those related to unscheduled hospi-
tal readmission. The demonstrated feasibility of delivering
all components of prescribed therapy is a testament to the
expertise of our multimodality team and the increased stam-
ina of selected patients who are treated rapidly. Experience
and clinical volume translate into better outcomes in many
realms of surgery.17 Requirements of experienced medical
and radiation oncologists and general thoracic surgeons may
limit the application of accelerated multimodality therapy to
large-volume centers.
Clinical Inferences
Accelerated multimodality therapy is equally valuable in
stage IIIA and stage IIIB disease, but pathologic response
cannot be predicted. Patients with N2 and N3 disease re-
spond similarly. Improved survival is seen in younger pa-
tients and those with nonsquamous histologic type, steril-
ization of mediastinal lymph nodes, and lower ypT.
Persistent ypN2 disease reduces the probability of long-term
survival but does not preclude it.
We thank Diane Baisden for database management, Barbara
Chonko and Tess Knerik for editorial assistance, and Brian Kohl-
bacher for graphics expertise.
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Appendix 1
Predictors of Survival
Two aspects of identifying predictors of survival were unconven-
tional, although, as has been pointed out to the readership of this
Journal, they are rapidly becoming mainstream in statistical circles
in one form or another: (1) careful consideration of the scaling of
continuous and ordinal variables and (2) variable selection on the
basis of random sampling (bootstrap bagging18).
For scaling, continuous and ordinal variables were assessed
univariably by decile risk analysis to suggest a set of transforma-
tions of scale that may be required to ensure good calibration to
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survival. Then 1000 bootstrap data sets were constructed and
analyzed by stepwise forward selection with a criterion for reten-
tion of variables in the models of P  .1. The 1000 models were
then subjected to analyses of correlated variables to quantify
frequency of occurrence of each cluster of variables. The most
frequently occurring member of a cluster appearing in at least 50%
of the bootstrap analyses was selected for the final multivariable
equation. The 50% rule equally balances false-positive and false-
negative identification of risk factors. For each continuous and
ordinal variable selected by the 50% rule, the scaling that most
frequently was observed in these 1000 models was selected as the
transformation incorporated into the final model.
Tabular results of multivariable analyses include an expression
of frequency of bootstrap occurrences (reliability of identification
of risk factors). Regression coefficients rather than hazard ratios
are presented because of the nonproportional nature of the mul-
tiphase hazard method and because of the transformations of scale
required for continuous and ordinal variables.
Discussion
Dr Robert Ginsberg (Toronto, Ontario, Canada). I would like to
congratulate Dr DeCamp and colleagues on a beautifully presented
study. I have a few comments.
The title of the talk appears to assert that this induction che-
moradiotherapy improves survival. I’m not sure that this has been
proved, because there are no valid data for comparison. Be that as
it may, I have a few questions for Dr DeCamp.
First, having had the experience of being in the SWOG study,
was there any difference in selection of your patients with positive
mediastinal lymph nodes? In other words, did you accept patients
with single-station lymph node disease? If so, how many were
there? Only 105 patients in a 6-year period were entered into this
trial. What happened to the other patients with stage IIIA and IIIB
disease at your institution during this time? How often was there
multistation bulky nodal disease among your patients?
When you compare your data with those of SWOG to conclude
that this accelerated chemoradiation improves survival, I have
some questions. In your induction therapy all patients necessarily
had to be hospitalized for their infusion, and 40% also had to be
hospitalized because of toxicity. This occurred before the opera-
tion in the induction phase and after the operation in the adjuvant
phase. Please comment on that and its comparison with the SWOG
4-week chemoradiation preoperative protocol. When you add up
the figures, your protocol is a 12-week protocol, and many induc-
tion chemoradiation protocols nowadays are 4 to 5 weeks of
induction chemoradiation followed by a 3- to 4-week rest, fol-
lowed by surgery. That’s a 10-week protocol.
Your resectability figures were unchanged, your patient com-
pliance figures were unchanged, and your downstaging was un-
changed relative to the SWOG trial—a very simple protocol, and
the time of treatment, even though it was “accelerated hyperfrac-
tionation” of the radiotherapy, was identical to SWOG at 12
weeks.
When you say that you’ve improved survival, what’s the cer-
tainty factor? It’s a decade later, and certainly all of us have had
patient selection changes in our induction therapy once we have
experience with more patients. So how certain can you be that
you’ve improved survival? Maybe you’ve just improved selection.
I also would like to know your center’s philosophy on resection
of T4 and N3 disease. At operation no attempt was made to dissect
the N3 nodes. How do you know that you didn’t have N3 disease
left behind, even though the N2 nodes were sterilized?
Also, you had 7 T4 tumors, and none of these patients under-
went an extended resection. Four of the T4 tumors were inopera-
ble, and in the other 3 cases, as far as I can tell, there was no
extended resection. All these patients underwent simple lobectomy
or pneumonectomy. What is the philosophy of your surgical ap-
proach after induction chemoradiation? Does it not matter any-
more that the original site of disease be removed? Is it okay just to
remove the primary site of disease and the regional lymph nodes,
leaving N3 nodes that may contain residual tumor?
Finally, now that you’ve prognosticated, how are you going to
deal with the 60-year-old patient with squamous cell cancer? And
how are you going to deal with the identification of persistent N2
disease, which you presume is also N3 disease, in the patients with
initial N3 disease after the chemoradiation, since none of those
patients survived?
Dr DeCamp. I appreciate your insightful comments, Dr Gins-
berg, and certainly recognize your preeminence in this field.
Regarding your question as to our philosophy about single-
station versus multistation, intracapsular versus extracapsular, or
bulky disease, we did not discriminate nor did we stratify our
outcome analysis according to these factors. It is our philosophy
that mediastinal nodal involvement is a marker for systemic dis-
ease, and without an effective systemic form of treatment as part
of our treatment plan, we do not believe that we need to discrim-
inate between those. All of that being said, I’m a firm believer that
there are good IIIBs and bad IIIBs and good IIIAs and bad IIIAs;
however, we tend to enroll all patients with reasonable perfor-
mance status and any N2 or N3 involvement in this accelerated
schema.
It is true that this is a toxic regimen. All of the patients are
inpatients during the first week of both the induction and the
adjuvant portions of treatment for continuous infusion chemother-
apy and for adequate hydration to prevent renal toxicity. It’s also
Appendix TABLE 1. Pathologic response to accelerated







No. % No. %
ypT*
0 12 16 2 8
1 28 37 9 35
2 27 36 9 35
3 2 3 3 12
4 6 8 3 12
ypN†
0 24 32 8 32
1 5 7 1 4
2 45 61 3 12
3 0 0 13 52
*Unknown in 4 cases.
†Unknown in 6 cases.
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